{"id":"probucol","rwe":[{"pmid":"41771453","year":"2026","title":"Caveolin-1 regulates cellular cholesterol homeostasis and its potential as an atherosclerosis therapy target.","finding":"","journal":"The Journal of steroid biochemistry and molecular biology","studyType":"Clinical Study"},{"pmid":"41721886","year":"2026","title":"Identification of Biomarkers Associated With Copper Metabolism in Ischemic Stroke Through Bulk RNA Sequencing and Mendelian Randomization Analysis.","finding":"","journal":"Cellular and molecular neurobiology","studyType":"Clinical Study"},{"pmid":"41601971","year":"2025","title":"Probucol: revisiting as a multifaceted therapeutic agent in atherosclerosis.","finding":"","journal":"Frontiers in pharmacology","studyType":"Clinical Study"},{"pmid":"41545617","year":"2026","title":"Female Infertility and Risk for Later-Life Cardiovascular Disease: Lessons from a Mouse Model of Human Cardiovascular Disease.","finding":"","journal":"Reproductive sciences (Thousand Oaks, Calif.)","studyType":"Clinical Study"},{"pmid":"41534646","year":"2026","title":"Probucol attenuates bone loss in APP/PS1 mice and ameliorates Aβ42-induced osteoblast dysfunction by regulating AKT/FOXO3a signaling pathway.","finding":"","journal":"Experimental gerontology","studyType":"Clinical Study"}],"tags":[{"label":"probucol","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Serine protease hepsin","category":"target"},{"label":"HPN","category":"gene"},{"label":"SIRT5","category":"gene"},{"label":"ALOX15","category":"gene"},{"label":"C10AX02","category":"atc"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Hypercholesterolemia","category":"indication"},{"label":"Hyperlipidemia","category":"indication"},{"label":"Approved 1970s","category":"decade"},{"label":"Anticholesteremic Agents","category":"pharmacology"},{"label":"Antimetabolites","category":"pharmacology"},{"label":"Antioxidants","category":"pharmacology"},{"label":"Hypolipidemic Agents","category":"pharmacology"},{"label":"Lipid Regulating Agents","category":"pharmacology"},{"label":"Protective Agents","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":154.227,"date":"","count":42,"signal":"Disease progression","source":"DrugCentral FAERS","actionTaken":"Reported 42 times (LLR=154)"}],"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=PROBUCOL","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:12:31.033229+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:12:37.835727+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PROBUCOL","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:12:38.590862+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: ATP-binding cassette sub-family A member 1 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:12:39.177895+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL608/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:12:39.064348+00:00"}},"allNames":"lorelco","offLabel":[],"synonyms":["probucol","biphenabid","bisphenabid","phenbutol","lorelco"],"timeline":[{"date":"1977-02-01","type":"positive","source":"DrugCentral","milestone":"FDA approval"}],"aiSummary":"Lorelco (PROBUCOL) is a small molecule drug originally developed by, currently owned by, and approved by the FDA in 1977 for the treatment of hypercholesterolemia and hyperlipidemia. It targets the serine protease hepsin and works by inhibiting the breakdown of cholesterol in the body. As an off-patent medication with no active Orange Book patents, Lorelco is available as a branded product. Key safety considerations include its low bioavailability of 5%. Lorelco's commercial status is off-patent, with no generic manufacturers.","approvals":[{"date":"1977-02-01","orphan":false,"company":"","regulator":"FDA"}],"brandName":"Lorelco","ecosystem":[{"indication":"Hypercholesterolemia","otherDrugs":[{"name":"alirocumab","slug":"alirocumab","company":"Sanofi Aventis"},{"name":"atorvastatin","slug":"atorvastatin","company":"Pfizer"},{"name":"cerivastatin","slug":"cerivastatin","company":"Bayer Pharms"},{"name":"cholestyramine","slug":"cholestyramine","company":"Bristol Myers"}],"globalPrevalence":390000000},{"indication":"Hyperlipidemia","otherDrugs":[{"name":"cholestyramine","slug":"cholestyramine","company":"Bristol Myers"},{"name":"choline fenofibrate","slug":"choline-fenofibrate","company":"Abbvie"},{"name":"clofibrate","slug":"clofibrate","company":""},{"name":"colestipol","slug":"colestipol","company":"Pharmacia And Upjohn"}],"globalPrevalence":390000000}],"mechanism":{"target":"Serine protease hepsin","novelty":"Follow-on","targets":[{"gene":"HPN","source":"DrugCentral","target":"Serine protease hepsin","protein":"Serine protease hepsin"},{"gene":"SIRT5","source":"DrugCentral","target":"NAD-dependent protein deacylase sirtuin-5, mitochondrial","protein":"NAD-dependent protein deacylase sirtuin-5, mitochondrial"},{"gene":"ALOX15","source":"DrugCentral","target":"Arachidonate 15-lipoxygenase","protein":"Arachidonate 15-lipoxygenase"},{"gene":"KCNH2","source":"DrugCentral","target":"Potassium voltage-gated channel subfamily H member 2","protein":"Potassium voltage-gated channel subfamily H member 2"},{"gene":"ABCA1","source":"DrugCentral","target":"ATP-binding cassette sub-family A member 1","protein":"ATP-binding cassette sub-family A member 1"}],"modality":"Small Molecule","drugClass":"probucol","explanation":"","oneSentence":"","technicalDetail":"Lorelco (probucol) is a lipophilic, weak base that inhibits the activity of hepsin, a serine protease involved in the breakdown of high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol."},"commercial":{"launchDate":"1977","_launchSource":"DrugCentral (FDA 1977-02-01, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2269","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=PROBUCOL","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PROBUCOL","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T15:25:45.027853","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:12:41.044792+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"dextrothyroxine","drugSlug":"dextrothyroxine","fdaApproval":"1967-04-14","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"ezetimibe","drugSlug":"ezetimibe","fdaApproval":"2002-10-25","patentExpiry":"Apr 30, 2026","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"mipomersen","drugSlug":"mipomersen","fdaApproval":"2013-01-29","patentExpiry":"Jan 29, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"lomitapide","drugSlug":"lomitapide","fdaApproval":"2012-12-21","patentExpiry":"Aug 19, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"evolocumab","drugSlug":"evolocumab","fdaApproval":"2015-08-28","relationship":"same-class"},{"drugName":"alirocumab","drugSlug":"alirocumab","fdaApproval":"2015-07-24","relationship":"same-class"},{"drugName":"bempedoic acid","drugSlug":"bempedoic-acid","fdaApproval":"2020-02-21","patentExpiry":"Mar 14, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"inclisiran","drugSlug":"inclisiran","fdaApproval":"2021-12-22","patentExpiry":"May 10, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"evinacumab","drugSlug":"evinacumab","fdaApproval":"2021-02-11","relationship":"same-class"}],"genericName":"probucol","indications":{"approved":[{"name":"Hypercholesterolemia","source":"DrugCentral","snomedId":13644009,"regulator":"FDA","usPrevalence":86000000,"globalPrevalence":390000000,"prevalenceMethod":"curated","prevalenceSource":"WHO Global Health Estimates, 2023"},{"name":"Hyperlipidemia","source":"DrugCentral","snomedId":55822004,"regulator":"FDA","usPrevalence":null,"globalPrevalence":390000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"dextrothyroxine","brandName":"dextrothyroxine","genericName":"dextrothyroxine","approvalYear":"1967","relationship":"same-class"},{"drugId":"ezetimibe","brandName":"ezetimibe","genericName":"ezetimibe","approvalYear":"2002","relationship":"same-class"},{"drugId":"mipomersen","brandName":"mipomersen","genericName":"mipomersen","approvalYear":"2013","relationship":"same-class"},{"drugId":"lomitapide","brandName":"lomitapide","genericName":"lomitapide","approvalYear":"2012","relationship":"same-class"},{"drugId":"evolocumab","brandName":"evolocumab","genericName":"evolocumab","approvalYear":"2015","relationship":"same-class"},{"drugId":"alirocumab","brandName":"alirocumab","genericName":"alirocumab","approvalYear":"2015","relationship":"same-class"},{"drugId":"bempedoic-acid","brandName":"bempedoic acid","genericName":"bempedoic acid","approvalYear":"2020","relationship":"same-class"},{"drugId":"inclisiran","brandName":"inclisiran","genericName":"inclisiran","approvalYear":"2021","relationship":"same-class"},{"drugId":"evinacumab","brandName":"evinacumab","genericName":"evinacumab","approvalYear":"2021","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06931834","phase":"","title":"Expanded Access Program for R007 (Probucol) Tablets in Adults With Mitochondrial Disease and Chronic Kidney Disease","status":"AVAILABLE","sponsor":"RiboNova Inc.","startDate":"","conditions":["Mitochondrial Disease","Chronic Kidney Disease"],"enrollment":0,"completionDate":""},{"nctId":"NCT02098460","phase":"PHASE4","title":"To Compare the Effect of Concomitant Administration of Probucol and Cilostazol With Probucol Single Treatment on the Atherosclerosis Related Markers (Including the Thickness of the Achilles Tendon) and Evaluate Safety (Based on Atorvastatin Treatment) in Severe Hypercholesterolemia Subject","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2013-10","conditions":["Severe Hypercholesterolemia"],"enrollment":300,"completionDate":"2016-03"},{"nctId":"NCT00823849","phase":"PHASE4","title":"Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related Biomarker","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2008-10","conditions":["Type 2 Diabetes Mellitus","Arteriosclerosis Obliterans"],"enrollment":200,"completionDate":"2010-03"},{"nctId":"NCT06604117","phase":"","title":"Efficacy of Probucol Combined with Statins Treatment for Ischemic Stroke","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2024-10-17","conditions":["Ischemic Stroke","Atherosclerosis of Artery","Lipid Disorder","Statin"],"enrollment":200,"completionDate":"2027-10"},{"nctId":"NCT03753555","phase":"PHASE4","title":"The Effect of InTensive Statin in Ischemic Stroke With inTracranial Atherosclerotic Plaques","status":"RECRUITING","sponsor":"General Hospital of Shenyang Military Region","startDate":"2018-12-01","conditions":["Stroke, Ischemic","Atherosclerosis, Cerebral"],"enrollment":100,"completionDate":"2026-11-30"},{"nctId":"NCT06225752","phase":"PHASE3","title":"Probucol for Symptomatic Intracranial and Extracranial Artery Stenosis","status":"RECRUITING","sponsor":"First Affiliated Hospital of Wannan Medical College","startDate":"2024-06-15","conditions":["Ischemic Stroke","TIA"],"enrollment":5452,"completionDate":"2026-10-31"},{"nctId":"NCT01142284","phase":"PHASE2","title":"Evaluation of Concomitant Administration of Cilostazol and Probucol on Biomarkers, Endothelial Function and Safety","status":"COMPLETED","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2010-05-19","conditions":["Peripheral Artery Disease"],"enrollment":80,"completionDate":"2012-12-18"},{"nctId":"NCT00549978","phase":"PHASE4","title":"Safety and Pharmacokinetics of Probucol and Cilostazol","status":"COMPLETED","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2007-10","conditions":["Healthy"],"enrollment":32,"completionDate":"2008-08"},{"nctId":"NCT01000467","phase":"PHASE4","title":"Pharmacokinetics Study for Probucol","status":"COMPLETED","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2009-02","conditions":["Healthy"],"enrollment":30,"completionDate":"2009-09"},{"nctId":"NCT03430284","phase":"PHASE4","title":"Multifactorial Intervention on Diabetes (MIDiab Study)","status":"UNKNOWN","sponsor":"Shandong Provincial Hospital","startDate":"2018-04-01","conditions":["Diabetes Mellitus, Type 2"],"enrollment":6300,"completionDate":"2022-12-31"},{"nctId":"NCT01291641","phase":"PHASE4","title":"Effect of Probucol and/or Cilostazol on Mean IMT in Patients With Coronary Heart dIsease","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2011-03","conditions":["Hyperlipidemias"],"enrollment":342,"completionDate":"2017-03"},{"nctId":"NCT03026465","phase":"PHASE4","title":"Vessel Injury in Relation With Strut Thickness Assessed by OCT","status":"COMPLETED","sponsor":"Fundacion Investigacion Interhospitalaria Cardiovascular","startDate":"2017-02-16","conditions":["Coronary Artery Disease"],"enrollment":50,"completionDate":"2018-07-27"},{"nctId":"NCT02707458","phase":"PHASE1,PHASE2","title":"Dosage and Efficacy of Probucol-induced apoE to Negate Cognitive Deterioration","status":"COMPLETED","sponsor":"Douglas Mental Health University Institute","startDate":"2016-04","conditions":["Dementia of the Alzheimer Type","Age-related Cognitive Decline","Mild Cognitive Impairment Due to Alzheimer Disease"],"enrollment":23,"completionDate":"2017-03"},{"nctId":"NCT01726816","phase":"PHASE2","title":"Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy","status":"COMPLETED","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2012-10","conditions":["Diabetic Nephropathy"],"enrollment":126,"completionDate":"2014-09"},{"nctId":"NCT00655330","phase":"NA","title":"Probucol Combined With Valsartan in Reducing Proteinuria in Diabetes Nephropathy","status":"UNKNOWN","sponsor":"Guangdong Provincial People's Hospital","startDate":"2008-05","conditions":["Type 2 Diabetes Mellitus","Nephropathy"],"enrollment":170,"completionDate":"2017-05"},{"nctId":"NCT02730390","phase":"","title":"Study on the Efficacy and Safety of Oral Probucol Tablets in Patients With Hyperlipidemia - Post-Marketing Surveillance","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical, Inc., Philippines","startDate":"2009-12","conditions":["Hyperlipidemia"],"enrollment":3087,"completionDate":"2013-08"},{"nctId":"NCT02483169","phase":"PHASE4","title":"PreventIon of IMT Progression in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage-IMT Study","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2009-06","conditions":["Brain Ischemia","Intracranial Hemorrhages"],"enrollment":800,"completionDate":"2016-12"},{"nctId":"NCT01013532","phase":"PHASE4","title":"PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2009-06","conditions":["Brain Ischemia","Intracranial Hemorrhages"],"enrollment":1600,"completionDate":"2016-12"},{"nctId":"NCT02196805","phase":"NA","title":"A Bioequivalence Study Comparing a Single Oral Intake of an Imported PROBUCOL Tablet(Lorelco) With a Marketed PROBUCOL Tablet(Chang Tai) in Chinese Healthy Volunteers","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2009-03","conditions":["Chinese Healthy Volunteers"],"enrollment":120,"completionDate":"2009-12"},{"nctId":"NCT00426348","phase":"PHASE4","title":"A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy","status":"COMPLETED","sponsor":"Guangdong Provincial People's Hospital","startDate":"2007-05","conditions":["Glomerulonephritis","IGA Nephropathy"],"enrollment":75,"completionDate":"2013-01"},{"nctId":"NCT01349010","phase":"PHASE3","title":"Efficacy and Safety of Imported Probucol to Treat Hyperlipidemia","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2011-04","conditions":["Hyperlipidemia"],"enrollment":264,"completionDate":"2013-02"},{"nctId":"NCT01590901","phase":"PHASE1","title":"Pharmacokinetics and Safety Study of Probucol by Multiple Administration in Healthy Male Subjects","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2012-02","conditions":["Healthy"],"enrollment":12,"completionDate":"2013-01"},{"nctId":"NCT01252056","phase":"PHASE4","title":"A Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2010-03","conditions":["Diabetic Nephropathy"],"enrollment":353,"completionDate":"2012-12"},{"nctId":"NCT00598533","phase":"PHASE4","title":"Efficacy Study of Rapamycin- vs. Zotarolimus-Eluting Stents to Reduce Coronary Restenosis","status":"COMPLETED","sponsor":"Deutsches Herzzentrum Muenchen","startDate":"2008-02","conditions":["Coronary Heart Disease"],"enrollment":3002,"completionDate":"2010-09"},{"nctId":"NCT01031667","phase":"PHASE4","title":"Synergistic Effect of Combination Therapy With Cilostazol and Probucol on Plaque Stabilization and Lesion Regression: Serial Intravascular Ultrasound and Virtual Histology Study(SECURE Study)","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2009-11","conditions":["Therapy"],"enrollment":118,"completionDate":"2011-06"},{"nctId":"NCT00823875","phase":"PHASE4","title":"Study of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker---atherosclerosis Cerebral Infarction Patient as Study Subject","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2009-03","conditions":["Atherosclerosis Cerebral Infarction"],"enrollment":200,"completionDate":"2010-07"},{"nctId":"NCT00276133","phase":"PHASE4","title":"Effects of Atorvastatin Versus Probucol on Small Dense LDL","status":"COMPLETED","sponsor":"Yokohama City University Medical Center","startDate":"2004-01","conditions":["Chronic Nephropathy"],"enrollment":24,"completionDate":"2007-05"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"NUI":"N0000146924","MMSL":"1235","NDDF":"002054","UNII":"P3CTH044XJ","VUID":"4018611","CHEBI":"CHEBI:8427","VANDF":"4018611","INN_ID":"2928","RXNORM":"203350","UMLSCUI":"C0033215","chemblId":"CHEMBL608","ChEMBL_ID":"CHEMBL608","KEGG_DRUG":"D00476","DRUGBANK_ID":"DB01599","PUBCHEM_CID":"4912","SNOMEDCT_US":"32474005","IUPHAR_LIGAND_ID":"7277","MESH_DESCRIPTOR_UI":"D011341"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"5%"},"publicationCount":1838,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"C10AX02","allCodes":["C10AX02"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 May","pmid":"41771453","title":"Caveolin-1 regulates cellular cholesterol homeostasis and its potential as an atherosclerosis therapy target.","journal":"The Journal of steroid biochemistry and molecular biology"},{"date":"2026 Feb 21","pmid":"41721886","title":"Identification of Biomarkers Associated With Copper Metabolism in Ischemic Stroke Through Bulk RNA Sequencing and Mendelian Randomization Analysis.","journal":"Cellular and molecular neurobiology"},{"date":"2025","pmid":"41601971","title":"Probucol: revisiting as a multifaceted therapeutic agent in atherosclerosis.","journal":"Frontiers in pharmacology"},{"date":"2026 Feb","pmid":"41545617","title":"Female Infertility and Risk for Later-Life Cardiovascular Disease: Lessons from a Mouse Model of Human Cardiovascular Disease.","journal":"Reproductive sciences (Thousand Oaks, Calif.)"},{"date":"2026 Feb","pmid":"41534646","title":"Probucol attenuates bone loss in APP/PS1 mice and ameliorates Aβ42-induced osteoblast dysfunction by regulating AKT/FOXO3a signaling pathway.","journal":"Experimental gerontology"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"withdrawn","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1977","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1977-02-01T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:12:41.044792+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}